MTOR and prostate cancer: This capability has been shown in a variety of cells, including PC-3 and C4-2 cells, prostate cancer cells, and colorectal cancer cells, where CDDO-Me inhibits the growth and causes cells death at intermediate–high concentrations (0.625–2.5 μM) through the inhibition of NF-κB, p-Akt, and mTOR [52].